ACE1	angiotensin I-converting enzyme,
ACE2	angiotensin-converting enzyme 2,
Ang-II	angiotensin II,
Ang-I	angiotensin I,
Ang 1–7	angiotensin 1–7,
APS	antiphospholipid syndrome,
ARBs	angiotensin II receptor blockers,
AT1R	angiotensin type 1 receptor,
AUC0–6h	area under the curve,
CAD	coronary artery disease,
CCBs	calcium channel blockers,
Cmax	maximum concentration,
CSG	Coronaviridae Study Group,
CYP	cytochrome P450,
DDIs	drug–drug interactions,
E	envelope,
ECMO	extracorporeal membrane oxygenation,
EMA	European Medicines Agency,
EUA	Emergency Use Administration,
FDA	Food and Drug Administration,
JAK-STAT	Janus kinase and signal transducer and activator of transcription,
Kb	kilobases
ICU	intensive care unit,
IDSA	Infectious Diseases Society of America,
IL-6	interleukin-6,
INR	international normalized ratio,
LQTs	long Q-T syndromes,
M	membrane,
MERS-CoV	Middle East respiratory syndrome coronavirus,
Mpro	main protease,
N	nucleoprotein,
NHC-TP	β-D-N4-hydroxycytidine 5′-triphosphate,
nsp-3	nonstructural protein 3,
ORF	open reading frames,
PAD	peripheral artery disease,
PLpro	papain-like protease,
RAAS	renin-angiotensin-aldosterone system,
RCTs	randomized clinical trials,
RdRp	RNA-dependent RNA polymerase,
RNA	ribonucleic acid,
RTP	remdesivir triphosphate,
SARS-CoV	severe acute respiratory syndrome coronavirus,
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2,
TMPRSS2	transmembrane serine protease 2,
UTR	untranslated regions,
VF	ventricular fibrillation,
VT	ventricular tachycardia,
WHO	World Health Organization,
WT	wild-type,
3CLPRO	3C-like protease.